Standard and Interpretation
Recommendations for diagnosis and treatment of ankylosing spondylitis
Huang Feng, Zhu Jian, Wang Yuhua, Zhang Jianglin, Jin Hongtao, Zhang Wen, Su Yin, Zhao Yan, on behalf of Chinese Rheumatology Association
Published 2022-08-01
Cite as Chin J Intern Med, 2022, 61(8): 893-900. DOI: 10.3760/cma.j.cn112138-20211226-00913
Abstract
Ankylosing spondylitis (AS) is a chronic inflammatory disease mainly affecting the sacroiliac joints, spine and peripheral joints. In China, standardized diagnosis and treatment of AS is still to be popularized. Based on the evidence and guidelines from China and other countries, Chinese Rheumatology Association developed standardization of diagnosis and treatment of AS. The purposes are: (1) to standardize the diagnosis and evaluation of AS; (2) to promote rational use of non-steroidal anti-inflammatory drugs, biological as well as traditional disease modifying anti-rheumatic drugs, so as to improve the patient′s quality of life.
Key words:
Spondylitis, ankylosing; Diagnosis; Treatment
Contributor Information
Huang Feng
Department of Rheumatology and Immunology, Chinese PLA General Hospital,First Medical Center, Beijing 100853, China
Zhu Jian
Department of Rheumatology and Immunology, Chinese PLA General Hospital,First Medical Center, Beijing 100853, China
Wang Yuhua
Department of Rheumatology and Clinical Immunology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China
Zhang Jianglin
Department of Rheumatology and Immunology, Chinese PLA General Hospital,First Medical Center, Beijing 100853, China
Jin Hongtao
Department of Rheumatology and Immunology, the Second Hospital of Heibei Medical University, Shijiazhuang 050000, China
Zhang Wen
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College,Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science &
Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China
Su Yin
Department of Rheumatology and Immunology, Peking University People′s Hospital, Beijing 100044, China
Zhao Yan
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College,Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science &
Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China
on behalf of Chinese Rheumatology Association
